Scientists at Northwestern University have redesigned a long-used chemotherapy drug into a far more powerful and precise treatment, capable of killing cancer cells up to 20,000 times more effectively than before, and with no detectable side effects in early testing. The findings, published in the Journal of the American Chemical Society and reported by SciTechDaily, mark a potential turning point in how cancer drugs are developed and delivered.
The team began with 5-fluorouracil (5-FU), a chemotherapy drug used for decades to treat several types of cancer. Although effective, 5-FU has long been associated with severe side effects because it cannot distinguish between healthy and cancerous cells. To change that, researchers rebuilt the drug at the molecular level into what’s known as a spherical nucleic acid, or SNA.
Each SNA is made by wrapping the drug in a shell of DNA strands that cancer cells naturally absorb. Once inside, enzymes break down the shell and release the treatment directly into the malignant cells. This approach boosted how efficiently the drug entered leukaemia cells by 12.5 times and dramatically reduced harm to healthy tissue.
Why this could transform cancer care
For decades, chemotherapy has been both a life-saving and punishing form of treatment. Its lack of precision often damages healthy organs and immune cells, leading to severe fatigue, nausea and infections. What makes this new approach stand out is how it combines existing cancer drugs with nanotechnology to make them more targeted, longer-lasting and less toxic.
In early animal studies, mice treated with the re-engineered drug saw slower tumour growth and better survival rates compared with those given conventional chemotherapy. Researchers say the method could be applied to a range of existing cancer treatments, potentially breathing new life into older drugs that have long been limited by toxicity or resistance.
Despite the promising results, human trials are still some way off. What works in a lab or in animal models often faces major obstacles in people, from immune responses to dosage control. The team behind the study emphasised that this discovery represents a “proof of concept” rather than a ready-to-use treatment.
There are also practical hurdles to overcome, including manufacturing costs, regulatory approval and ensuring that the therapy can be produced at scale without losing its precision. Still, many in the scientific community see it as a strong example of how existing cancer drugs can be made safer and more efficient through nanotechnology.
The idea that a long-established drug like 5-FU could be reworked into something vastly more effective offers genuine hope for patients and doctors alike. Rather than relying solely on discovering new molecules, researchers are showing how old drugs can be given a second life through better design.
If these early findings hold up in clinical trials, this method could reshape cancer care, offering treatments that attack tumours more aggressively while sparing the body the worst of chemotherapy’s toll. It’s a reminder that sometimes innovation isn’t about finding something entirely new, but about rethinking what’s already in front of us, and using it far more wisely.